- Previous Close
17.49 - Open
17.15 - Bid 16.55 x 200
- Ask 21.06 x 200
- Day's Range
16.38 - 17.90 - 52 Week Range
4.27 - 18.51 - Volume
1,662,315 - Avg. Volume
1,132,753 - Market Cap (intraday)
1.61B - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-0.47 - Earnings Date Nov 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
25.67
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
ars-pharma.comRecent News: SPRY
View More
Performance Overview: SPRY
Trailing total returns as of 11/12/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SPRY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SPRY
View MoreValuation Measures
Market Cap
1.61B
Enterprise Value
1.39B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.20k
Price/Book (mrq)
7.48
Enterprise Value/Revenue
2.78k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.75%
Return on Equity (ttm)
-19.34%
Revenue (ttm)
500k
Net Income Avi to Common (ttm)
-44.84M
Diluted EPS (ttm)
-0.47
Balance Sheet and Cash Flow
Total Cash (mrq)
218.74M
Total Debt/Equity (mrq)
0.07%
Levered Free Cash Flow (ttm)
-26.33M
Research Analysis: SPRY
View MoreCompany Insights: SPRY
SPRY does not have Company Insights